Literature DB >> 34557982

Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.

Chun-Dong Zhang1,2, Hideyuki Takeshima1, Shigeki Sekine3, Satoshi Yamashita1, Yu-Yu Liu1, Naoko Hattori1, Hiroyuki Abe4, Hiroharu Yamashita2, Masahide Fukuda1, Yu Imamura5, Tetsuo Ushiku4, Hitoshi Katai6, Hiroshi Makino7, Masayuki Watanabe5, Yasuyuki Seto2, Toshikazu Ushijima8.   

Abstract

BACKGROUND: Prediction of tissue origin of esophagogastric junction (EGJ) adenocarcinomas can be important for therapeutic decision, but no molecular marker is available. Here, we aimed to develop such a marker taking advantage of tissue-specific profiles of DNA methylation.
METHODS: DNA methylation profiles of gastric adenocarcinomas (GACs) were obtained by an Infinium HumanMethylation450 BeadChip array, and those of esophageal adenocarcinoma (EACs) were obtained from the TCGA database. DNA from formalin-fixed paraffin-embedded (FFPE) samples was analyzed by bisulfite pyrosequencing.
RESULTS: In the screening set, 51 of 145,841 CpG sites in CpG islands were methylated at significantly higher levels in 30 GACs compared to those in 30 EACs. Among them, SLC46A3 and cg09177106 were unmethylated in all the 30 EACs. Predictive powers of these two markers were successfully confirmed in an independent validation set (18 GACs and 18 EACs) (SLC46A3, sensitivity = 77.8%, specificity = 100%; cg09177106, sensitivity = 83.3%, specificity = 94.4%), and could be applied to FFPE samples (37 GACs and 18 EACs) (SLC46A3, P = 0.0001; cg09177106, P = 0.0028). On the other hand, EAC-specific markers informative in the FFPE samples could not be isolated. Using these GAC-specific markers, nine of 46 (19.6%) TCGA EGJ adenocarcinomas were predicted to be GACs.
CONCLUSIONS: Two GAC-specific markers, SLC46A3 and cg09177106, had a high specificity for identifying the tissue origin of EGJ adenocarcinoma.
© 2021. The International Gastric Cancer Association and The Japanese Gastric Cancer Association.

Entities:  

Keywords:  Barrett’s esophagus; DNA methylation; Epigenetics; Esophageal cancer; Gastric cancer; Molecular marker

Mesh:

Year:  2021        PMID: 34557982     DOI: 10.1007/s10120-021-01252-y

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  41 in total

Review 1.  Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers.

Authors:  Arnulf H Hölscher; Simon Law
Journal:  Gastric Cancer       Date:  2019-11-06       Impact factor: 7.370

2.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

3.  Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.

Authors:  J Rüdiger Siewert; M Feith; M Werner; H J Stein
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

4.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

Review 5.  Western strategy for EGJ carcinoma.

Authors:  Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni
Journal:  Gastric Cancer       Date:  2016-12-30       Impact factor: 7.370

6.  Oesophagogastric junction adenocarcinoma: which therapeutic approach?

Authors:  Christophe Mariette; Guillaume Piessen; Nicolas Briez; Caroline Gronnier; Jean Pierre Triboulet
Journal:  Lancet Oncol       Date:  2010-11-23       Impact factor: 41.316

Review 7.  The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.

Authors:  Manfred P Lutz; John R Zalcberg; Michel Ducreux; Antoine Adenis; William Allum; Daniela Aust; Fatima Carneiro; Heike I Grabsch; Pierre Laurent-Puig; Florian Lordick; Markus Möhler; Stefan Mönig; Radka Obermannova; Guillaume Piessen; Angela Riddell; Christoph Röcken; Franco Roviello; Paul Magnus Schneider; Stefan Seewald; Elizabeth Smyth; Eric van Cutsem; Marcel Verheij; Anna Dorothea Wagner; Florian Otto
Journal:  Eur J Cancer       Date:  2019-03-15       Impact factor: 9.162

8.  Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; David J Bentrem; Joseph Chao; Carlos Corvera; Prajnan Das; Crystal S Denlinger; Peter C Enzinger; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; Stephen Leong; Quan P Ly; Kristina A Matkowskyj; Michael McNamara; Mary F Mulcahy; Ravi K Paluri; Haeseong Park; Kyle A Perry; Jose Pimiento; George A Poultsides; Robert Roses; Vivian E Strong; Georgia Wiesner; Christopher G Willett; Cameron D Wright; Nicole R McMillian; Lenora A Pluchino
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 11.908

9.  Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia.

Authors:  Kenneth E L McColl; James J Going
Journal:  Gut       Date:  2010-03       Impact factor: 23.059

10.  Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study.

Authors:  Yukinori Kurokawa; Hiroya Takeuchi; Yuichiro Doki; Shinji Mine; Masanori Terashima; Takushi Yasuda; Kazuhiro Yoshida; Hiroyuki Daiko; Shinichi Sakuramoto; Takaki Yoshikawa; Chikara Kunisaki; Yasuyuki Seto; Shigeyuki Tamura; Toshio Shimokawa; Takeshi Sano; Yuko Kitagawa
Journal:  Ann Surg       Date:  2021-07-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.